We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Titan Pharmaceuticals Inc | NASDAQ:TTNP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 2.69% | 6.88 | 6.31 | 37.20 | 6.88 | 6.81 | 6.88 | 1,088 | 05:00:04 |
Name and Address of Beneficial Owner
(1)
|
| |
Shares
Beneficially Owned (2) |
| |
Percent of Shares
Beneficially Owned |
| ||||||
Joseph A. Akers
|
| | | | 39,819 (3) | | | | | | * | | |
Sunil Bhonsle
|
| | | | 635,571 (4) | | | | | | 2.9 % | | |
Rajinder Kumar, Ph.D.
|
| | | | 2,917 (5) | | | | | | * | | |
M. David MacFarlane, Ph.D.
|
| | | | 75,011 (6) | | | | | | * | | |
James R. McNab, Jr.
|
| | | | 126,819 (7) | | | | | | * | | |
Marc Rubin, M.D.
|
| | | | 701,628 (8) | | | | | | 3.2 % | | |
Scott A. Smith
|
| | | | 2,917 (9) | | | | | | * | | |
Robert E. Mead
|
| | | | 1,405,000 (10) | | | | | | 6.6 % | | |
All executive officers and directors as a group (7 persons)
|
| | | | 1,584,682 | | | | | | 7.1 % | | |
Name
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Stock
Awards ($) |
| |
Options
Awards ($) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Nonqualified
Deferred Compensation Earnings ($) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| |||||||||||||||||||||
Joseph A. Akers
(1)
|
| | | $ | 57,500 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 57,500 | | |
Victor J. Bauer
(2)
(7)
|
| | | | 32,083 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 32,083 | | |
Eurelio M. Cavalier
(3)
|
| | | | 57,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 57,500 | | |
M. David MacFarlane
(4)
|
| | | | 52,083 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 52,083 | | |
James R. McNab, Jr.
(5)
|
| | | | 54,583 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,583 | | |
Ley S. Smith
(6)
(7)
|
| | | | 32,083 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 32,083 | | |
Event
|
| |
Award Vesting
|
| |
Exercise Term
|
|
•
Termination by us for Reason Other than Cause, Disability or Death
|
| |
•
Forfeit Unvested Options
|
| |
•
Earlier of: (1) 90 days or
(2) Remaining Option Period
|
|
•
Termination for Disability, Death or Retirement
|
| |
•
Forfeit Unvested Options
|
| |
•
Earlier of: (1) 2 years or
(2) Remaining Option Period
|
|
•
Termination for Cause
|
| |
•
Forfeit Vested and Unvested Options
|
| |
•
Expire
|
|
•
Other Termination
|
| |
•
Forfeit Unvested Options
|
| |
•
Earlier of: (1) 90 days or
(2) Remaining Option Period
|
|
•
Change in Control
|
| |
•
Accelerated*
|
| |
•
*
|
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Options
Awards ($) (1) |
| |
Stock
Awards ($) (1) |
| |
All Other
Compensation ($) |
| |
Total
Compensation ($) |
| |||||||||||||||||||||
Marc Rubin, M.D.
Executive Chairman |
| | | | 2016 | | | | | $ | 295,000 | | | | | $ | 73,000 | | | | | $ | 245,311 | | | | | $ | — | | | | | $ | — | | | | | $ | 613,311 | | |
| | | 2015 | | | | | | 210,000 | | | | | | — | | | | | | 473,719 | | | | | | — | | | | | | — | | | | | | 683,719 | | | ||
| | | 2014 | | | | | | 210,000 | | | | | | — | | | | | | — | | | | | | 66,000 | | | | | | — | | | | | | 276,000 | | | ||
Sunil Bhonsle
Chief Executive Officer, President and Principal Financial Officer |
| | | | 2016 | | | | | | 395,000 | | | | | | 96,000 | | | | | | 276,323 | | | | | | — | | | | | | — | | | | | | 767,323 | | |
| | | 2015 | | | | | | 300,000 | | | | | | — | | | | | | 496,767 | | | | | | — | | | | | | — | | | | | | 796,767 | | | ||
| | | 2014 | | | | | | 300,000 | | | | | | — | | | | | | — | | | | | | 66,000 | | | | | | — | | | | | | 366,000 | | |
Name
|
| |
Grant
Date |
| |
Approval
Date (1) |
| |
Number of
Shares of Common Stock Underlying Awards (#) |
| |
Exercise or
Base Price of Option Awards ($/Sh) |
| |
Grant Date Fair
Value of Stock and Option Awards ($) (2) |
| |||||||||||||||
Marc Rubin, M.D.
|
| | | | 2/02/2016 | | | | | | 2/01/2016 | | | | | | 79,100 (3) | | | | | $ | — | | | | | $ | 245,311 | | |
Sunil Bhonsle
|
| | | | 2/02/2016 | | | | | | 2/01/2016 | | | | | | 89,100 (3) | | | | | $ | — | | | | | $ | 276,323 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Awards (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Awards (#) Unexercisable |
| |
Exercise
Price ($) |
| |
Expiration Date
|
| ||||||||||||
Marc Rubin, M.D.
|
| | | | 79,546 | | | | | | — | | | | | $ | 13.20 | | | | | | 10/01/2017 | | |
| | | 1,364 | | | | | | — | | | | | | 8.36 | | | | | | 5/30/2018 | | | ||
| | | 18,182 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 2,729 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 51,818 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 111,819 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 27,273 | | | | | | — | | | | | | 7.70 | | | | | | 4/15/2021 | | | ||
| | | 45,455 | | | | | | — | | | | | | 6.32 | | | | | | 1/3/2022 | | | ||
| | | 36,364 | | | | | | — | | | | | | 3.30 | | | | | | 3/16/2025 | | | ||
| | | 45,450 | | | | | | 45,450 (1) | | | | | | 5.10 | | | | | | 12/14/2025 | | | ||
| | | 32,958 | | | | | | 46,142 (1) | | | | | | 5.10 | | | | | | 02/02/2026 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Awards (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Awards (#) Unexercisable |
| |
Exercise
Price ($) |
| |
Expiration Date
|
| ||||||||||||
Sunil Bhonsle
|
| | | | 13,939 | | | | | | — | | | | | | 17.21 | | | | | | 1/3/2017 | | |
| | | 909 | | | | | | — | | | | | | 8.36 | | | | | | 5/30/2018 | | | ||
| | | 18,182 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 1,819 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 70,910 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 56,364 | | | | | | — | | | | | | 4.34 | | | | | | 5/17/2019 | | | ||
| | | 36,364 | | | | | | — | | | | | | 7.70 | | | | | | 4/15/2021 | | | ||
| | | 54,546 | | | | | | — | | | | | | 6.32 | | | | | | 1/3/2022 | | | ||
| | | 43,637 | | | | | | — | | | | | | 3.30 | | | | | | 3/16/2025 | | | ||
| | | 45,450 | | | | | | 45,450 (1) | | | | | | 5.10 | | | | | | 12/14/2025 | | | ||
| | | 37,125 | | | | | | 51,975 (1) | | | | | | 5.10 | | | | | | 2/02/2026 | | |
| | |
2016
|
| |
2015
|
| ||||||
Audit Fees
|
| | | $ | 164,688 | | | | | $ | 149,091 | | |
Audit-Related Fees
|
| | | | 41,037 | | | | | | — | | |
Tax Fees
|
| | | | 26,000 | | | | | | 32,425 | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total
|
| | | $ | 231,725 | | | | | $ | 181,516 | | |
|
☐
FOR all nominees listed below (except as marked to the contrary below)
|
| |
☐
WITHHOLD AUTHORITY to vote for all nominees listed below
|
|
| | | |
|
☐
FOR
|
| |
☐
AGAINST
|
| |
☐
ABSTAIN
|
|
|
☐
FOR
|
| |
☐
AGAINST
|
| |
☐
ABSTAIN
|
|
| Date: __________, 2017 | | |
Signature
|
|
| | | |
Signature if held jointly
|
|
1 Year Titan Pharmaceuticals Chart |
1 Month Titan Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions